Study Purpose: This study looks at how safe a medicine called astegolimab is for people with Chronic Obstructive Pulmonary Disease (COPD) over a long time. COPD is a lung disease that makes it hard to breathe. This study is for people who have already been in a similar study for 52 weeks.
Who Can Join: To join, you must have finished the 52-week treatment in one of the earlier studies named GB43311 or GB44332. You cannot join if you stopped the earlier study early, had any major problems following study rules, or have any new serious heart or lung illnesses.
- The study checks safety after a 52-week prior treatment.
- Participants must have completed specific earlier studies.
- New serious health issues may disqualify participation.
This study helps understand how safe astegolimab is for people with COPD over a long time. It’s important to follow all the study rules and report any new health issues to the doctors. If you think you might qualify, talk to your doctor about joining.